国际早期COVID-19疫情期间肿瘤科室组织与癌症管理优先事项推荐综述:在低中收入国家的适用性
本文综述了COVID-19大流行期间国际发布的肿瘤科室组织与癌症管理优先事项推荐,旨在按癌种汇总并形成日常实践综合,以保护患者和员工并调整抗癌治疗交付。作者同时讨论这些推荐在不同组织、有限资源和不同约束的低中收入国家的适用性。
要点
- 按癌种汇总国际COVID-19肿瘤管理推荐,形成日常实践综合。
- 推荐需兼顾患者/肿瘤标准与工具可及性以调整抗癌治疗。
- 讨论推荐在低中收入国家的适用性受组织与资源限制。
核心结论
- 国际COVID-19肿瘤管理推荐可直接用于欧洲,但在低中收入国家可能因组织、资源和约束不同而不完全适用。
研究设计与样本
- 综述类:汇总并按癌种综合国际早期COVID-19肿瘤科室组织与癌症管理优先事项推荐,并讨论其在低中收入国家的适用性。
主要发现
- 受影响国家的肿瘤科室需快速调整医疗系统护理并建立新的组织与优先事项。
- 已报告大量推荐和治疗选择以优化慢性病和癌症患者的治疗交付。
临床怎么用
- 日常实践可参照按癌种汇总的推荐,结合患者/肿瘤标准和工具可及性调整抗癌治疗交付。
- 在低中收入国家应用时需考虑不同组织、有限手段和不同约束。
局限性
- 推荐在低中收入国家的适用性受不同组织、有限资源和不同约束限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints.
引用
- Belkacemi Y, Grellier N, Ghith S, et al. A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. Eur J Cancer. 2020. PMID: 32580130. doi:10.1016/j.ejca.2020.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。